BMC CANCER《BMC癌症》（可官网投稿）

杂志简称：bmc cancer
中文译名：《bmc癌症》
收录属性：scie（2024版）, 目次收录（维普）,英文期刊,
自引率：1.90%
投稿方向：医学、oncology 肿瘤学

SCI/E期刊基本信息

出版周期：其它 地区：英国
中科院分区：3区
是否TOP：非TOP期刊
是否综述：非综述期刊
是否OA：OA期刊
国际标准刊号：ISSN 1471-2407；EISSN1471-2407
杂志语言：英语
出版国家：英国

杂志官网 联系方式

出版地址：CAMPUS,4 CRINAN ST,LONDON,ENGLAND,N1 9XW
杂志邮箱：
投稿网址：https://author-welcome.nature.com/12885
杂志官方网址：https://bmccancer.biomedcentral.com/
出版商网址：https://www.biomedcentral.com/

杂志投稿要求

投稿须知【杂志社官方网站信息】

Submission guidelines

Our 3-step submission process

Before you submit

Now you’ve identified a journal to submit to, there are a few things you should be familiar with before you submit.

Make sure you are submitting to the most suitable journal – Aims and scope

Understand the costs and funding options – Fees and funding

Make sure your manuscript is accurate and readable – Language editing services

Understand the copyright agreement – Copyright

Ready to submit

To give your manuscript the best chance of publication, follow these policies and formatting guidelines.

General formatting rules for all article types – Preparing your manuscript

Make sure your submission is complete – Prepare supporting information

Copyright and license agreement – Conditions of publication

Read and agree to our Editorial Policies – Editorial policies

Submit and promote

After acceptance, we provide support so your article gains maximum impact in the scientific community and beyond.

Please note that manuscript can only be submitted by an author of the manuscript and may not be submitted by a third party.

Who decides whether my work will be accepted? – Peer-review policy

Want to submit to a different journal? – Manuscript transfers

Spreading the word – Promoting your publication

Submit manuscript

Aims and scope

BMC Cancer is an open access, peer-reviewed journal that considers articles on all aspects of cancer research, including the pathophysiology, prevention, diagnosis and treatment of cancers. The journal welcomes submissions concerning molecular and cellular biology, genetics, epidemiology, and clinical trials.

The journal welcomes manuscripts in the following broad areas of research:

Cell and molecular biology including all aspects of tumor biology from a molecular and cellular point of view. Topics of interest include animal models, hypoxia, angiogenesis, metastasis, cellular signaling, cancer stem cells, DNA damage and repair, cell cycle and apoptosis.

Biomarker studies we will publish studies of diagnostic and prognostic markers which may ultimately be applicable in a clinical setting. Submissions need to be REMARK compliant as established in NCI-EORTC's "Reporting Recommendations for Tumor Marker Prognostic Studies" (J Clin Oncol 23:9067, 2005) and "Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): An Abridged Explanation and Elaboration" (J Natl Cancer Inst . 2018 Aug 1;110(8):803-811.). They should report biomarkers that have a clear biologic relevance to a particular tumor type and be validated in at least one independent validation cohort and with biological validation in vitro or in vivo. Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation will not be considered at BMC Cancer.

Epidemiology, prevention and public health related cancer research including all aspects of cancer epidemiology including risk factors for disease initiation and development, social determinants, environmental, behavioural, and occupational correlates, and the impact of health policies, practices and interventions on the community.

Experimental therapeutics and drug development including all aspects of preclinical investigations on therapeutic agents. It welcomes submissions concerning anti-cancer drug discovery and development, and targeted therapies.

Genetics, genomics and epigenetics including all aspects of genome-scale analysis, functional genomics, genetic association studies, pharmacogenomics and epigenetics in relation to cancer biology, diagnosis and therapy.

Tumour immunology including on all aspects of infectious agents associated with cancer and tumor immunology. Topics of interest include, but are not limited to, tumor immunity, immunotherapy, cancer vaccines, viral carcinogenesis and virus-host interactions.

Therapy studies with focus on clinical research that impacts on the treatment of cancer using systemic chemotherapy, immunotherappy, targeted therapy, and radiation. We further welcome submissions on research looking at therapy resistance mechanisms.

Surgical oncology with focus on clinical research that impacts on the diagnosis and treatment of cancer using surgery, diagnostic imaging, interventional therapeutics, and surgical pathology.

Survivorship research with focuses on research related to post-treatment cancer survivors. Topics of interest include, but are not limited to, long-term studies on adverse events/side effects of cancer treatment, mortality of young cancer survivors, policy-related research that can impact the quality of care and quality of life of cancer survivors, recent guidelines for investigation of complications after treatment in child and adult cancers.

Systems biology, post-genomic analysis and emerging technologies including all all aspects of the function of biological systems at the molecular and cellular level, in particular those addressing network modeling, quantitative analyses and the integration of different levels of information. Topics of interest include, but are not limited to, deep sequencing-based technologies, computational biology and machine learning in relation to cancer biology.

Fees and funding

Article-processing charges

Open access publishing is not without costs. BMC Cancer therefore levies an article-processing charge of £1790.00/$2570.00/€2170.00 for each article accepted for publication, plus VAT or local taxes where applicable.

If the corresponding author's institution participates in our open access membership program, some or all of the publication cost may be covered (more details available on the membership page). We routinely waive charges for authors from low-income countries. For other countries, article-processing charge waivers or discounts are granted on a case-by-case basis to authors with insufficient funds. Authors can request a waiver or discount during the submission process. For further details, see our article-processing charge page.

BMC provides a free open access funding support service to help authors discover and apply for article processing charge funding. Visit our OA funding and policy support page to view our list of research funders and institutions that provide funding for APCs, and to learn more about our email support service.

For more information on APCs please see our Journal Pricing FAQs